PolySearch2 - Result Details

(2015) Bisphenol A, benzophenone-type ultraviolet filters, and phthalates in relation to uterine leiomyoma. Environmental research;Environ. Res.;2015 Feb;137:101-7

Bisphenol A, benzophenone-type UV filters, and phthalates are chemicals in high production and use including in a range of personal care products. Exposure of humans to these chemicals has been shown to affect endocrine function. Although short-lived, widespread exposure may lead to continual opportunity for these chemicals to elicit health effects in humans. The association of these chemicals with incident uterine leiomyoma, an estrogen sensitive disease, is not known. Urinary concentrations of Bisphenol A (BPA), five benzophenone-type UV filters (2-hydroxy-4-methoxybenzophenone (2OH-4MeO-BP), 2,4-dihydroxybenzophenone (2,4OH-BP), 2,2x3-dihydroxybenzophenone (2,2x3OH-4MeO-BP), 2,2x34,4x3-tetrahydroxybenzophenone (2,2x34,4x3OH-BP), and 4-hydroxybenzophenone (4OH-BP), and 14 phthalate monoesters were quantified in 495 women who later underwent laparoscopy/laparotomy at 14 clinical sites for the diagnosis of fibroids. Significantly higher geometric mean creatinine-corrected concentrations of BPA, 2,4OH-BP, and 2OH-4MeO-BP were observed in women with than without fibroids [BPA: 2.09Aug/g vs. 1.46Aug/g p=0.004; 2,4OH-BP:11.10Aug/g vs. 6.71Aug/g p=0.01; 2OH-4MeO-BP: 11.31Aug/g vs. 6.10Aug/g p=0.01]. Mono-methyl phthalate levels were significantly lower in women with than without fibroids (1.78Aug/g vs. 2.40Aug/g). However, none of the exposures were associated with a significant odds ratio even when adjusting for relevant covariates. There was a lack of an association between select nonpersistent chemicals and the odds of a fibroid diagnosis.

MEDLINE 25531814 : Bisphenol A, benzophenone-type ultraviolet filters, and phthalates in relation to uterine leiomyoma.

This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $900 million in funding from the federal government.